

1 Attention bias at baseline does not moderate the
2 effect of attention bias modification for depressive
3 symptoms

4 Hallvard Solbø Hagen¹, Jan Ivar Røssberg¹, Catherine J. Harmer^{2, 3}, Rune Jonassen⁴, Nils Inge Landrø²
5 Ragnhild Bø²

6 ¹Institute of Clinical Medicine, University of Oslo, Norway

7 ²Clinical Neuroscience Research Group, Department of Psychology, University of Oslo, Norway

8 ³Department of Psychiatry, Oxford University, UK

9 ⁴Faculty of Health Sciences, Oslo Metropolitan University, Norway

10 Corresponding author at: h.s.hagen@medisin.uio.no (HSH)

11

12

13

14

15

16

17

18

19

20

21

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

22 Abstract

23 **Background:** Clinical trials of Attention Bias Modification for depressive symptoms have consistently
24 produced small effect sizes and mixed results. Therefore, identifying subpopulations for whom this
25 intervention works has been called for. Considering the intended mechanism behind Attention Bias
26 Modification, change of attentional bias, the level of bias at baseline may moderate its efficacy.

27 **Methods:** Participants with a history of depression (N=301) were randomized to receive two daily
28 sessions of either Attention Bias Modification or sham for 14 days. A response-based attention bias
29 score was calculated, and a moderator analysis was run at post-intervention and 1-month follow-up
30 measured by change in Hamilton Depression Rating Scale and Beck Depression Inventory II,
31 respectively.

32 **Results:** Baseline attention bias did not significantly moderate the effect of Attention Bias
33 Modification on any of the time points or depression measures.

34 **Conclusions:** Baseline attentional bias was not found useful for characterizing subgroups more likely
35 to benefit from ABM for depressive symptoms.

36

37 Introduction

38 Depression is a leading cause of disability worldwide (GBD 2019 Mental Disorders Collaborators
39 2022). Current treatment options are effective [2], but a considerable proportion of patients
40 experience residual symptoms and frequent relapses. Therefore, to improve treatment outcomes,
41 novel approaches are required. Attention Bias (AB), the selective attention to negatively valenced
42 information, is theorized to be a central mechanism of depression [3]. Meta-analyses show that
43 patients with both current (Peckham et al., 2010; Suslow et al., 2020) and remitted depression [6,7]
44 show AB for negative stimuli.

45 Attention Bias Modification (ABM) was developed to reduce negative AB. In a seminal study, it was
46 revealed that modification of AB decreased mood reactivity following a mood induction procedure
47 [8]. In the following decades, ABM has been found to decrease depressive symptoms (e.g. Hsu et al.,
48 2021; Jonassen et al., 2019) but effects have been small or non-significant in the early meta-analyses
49 [11–13]. Two more recent depression-specific meta-analyses showed small to moderate effect sizes
50 [14,15].

51 Under the requirements of precision medicine, a more fine-grained approach for personalizing
52 treatment has been advocated by the Lancet Commission of Depression [16]. Various potential
53 moderators have been put to the test to define participant characteristics that may predict the
54 treatment outcome of ABM. In anxiety research, several moderators have been identified (MacLeod
55 et al., 2019), but few moderators have been found when investigating depression. A higher baseline
56 score of anxiety [18] and baseline rumination [19] have been found to moderate the effect, though
57 non-significant moderator effects have also been reported [4]. A major problem in some of these
58 studies has been lack of statistical power.

59 Change in AB is the assumed causative agent of ABM and we therefore sought to analyze whether
60 the baseline level of AB would moderate the effect of ABM. A significant moderating effect of
61 baseline AB has been found in generalized social phobia [20], but has not, to our knowledge, been
62 tested appropriately in depressed patients. In a study on non-depressed college students, a
63 moderating effect was absent in a three-armed RCT (N=77), using a dot-probe task [21]. However,
64 pre-selecting individuals based on moderate levels of AB in eye-tracking in a group of depressed
65 individuals was found to have a lasting effect on depression [9], but moderation was not analyzed.
66 This may indicate a more beneficial effect for individuals with more negative ABs.

67 The reliability of the traditional AB computation has repeatedly been found to be unacceptably low
68 [22–25]. This makes it both unapt for clinical use as it cannot be used at an individual level but also
69 reduces power [26]. We therefore applied a novel computational model that has been shown to

70 increase reliability to acceptable levels [27]. Rather than a total trial average of reaction times, this
71 response-based computation is more sensitive to fluctuations in attention. From our material, three
72 of the indexes can be calculated: vigilance, avoidance and the ratio between the absolute numbers.
73 As the group mean AB has been found to be toward dysphoric images across different measurement
74 techniques [5,7], we chose vigilance as the metric of AB in this analysis.

75 Baseline AB could be used as an indicator of treatment strategy and this could help tailor treatment,
76 and consequently a more personalized treatment. We hypothesized that the baseline level of AB in a
77 sample of previously depressed participants would moderate the effect of ABM on depression
78 outcome with increasing effect for those displaying more extreme baseline AB scores.

79

80 **Methods**

81 **Participants**

82 The data analyzed in this paper is based on a previous double-blinded randomized controlled
83 trial including participants with residual depressive symptoms with preregistered moderator
84 analyses. Participants were recruited after receiving treatment as outpatients and were
85 included in the study between May 6, 2014 to September 27, 2016 (ClinicalTrials.gov,
86 number NCT02658682; n=301) [10]. The study received approval from the Regional Ethical
87 Committee for Medical and Health Research for Southern Norway (2014/217/REK Sør-Øst D)
88 and informed written consent was obtained prior to enrollment. Participants aged 18-65
89 were included if they, according to the Norwegian version of MINI International
90 Neuropsychiatric Interview 6.0.0 (M.I.N.I.), met the criteria for recurrent remitted Major
91 Depressive Disorder (MDD), and having at least two prior episodes of depression. Exclusion
92 criteria were head trauma, current substance abuse, psychosis, bipolar disorder,

93 neurological disorders, and attention deficit disorders. The data was accessed in March
94 2024.

95 **Randomization**

96 Participants were randomly allocated 1:1 to receive either active ABM or a sham condition and were
97 provided with laptops to run the intervention at home. The laptops were pre-programmed by an
98 independent lab technician, thus ensuring blindness to study allocation for both participants and
99 outcome assessors. The study followed an ITT approach, implying that 37 participants who were
100 currently depressed and therefore wrongfully included were subjected to analysis.

101 **Intervention**

102 The ABM procedure was based on the dot probe procedure and was similar to the one described in
103 Browning et al. (2012). Participants were instructed to perform the task, consisting of 96 trials and
104 lasting for approx. 5-7 min, twice daily for 14 days. Each trial started with a fixation cross, followed by
105 a vertically positioned pair of images of faces and these were paired positive-negative, positive-
106 neutral and negative-neutral. All pictures were from 4 databases: the Karolinska directed emotional
107 faces database (Lundqvist et al., 1998), Matsumoto and Ekman's Japanese and Caucasian Facial
108 Expressions of Emotion (Biehl et al., 1997) NimStim (Tottenham et al., 2009) and Ekman Pictures of
109 Facial Affect (Ekman & Friesen, 1976). The stimuli lasted 500ms or 1000ms (1:1) and was randomly
110 presented in either the first or last half of the session. The emotions expressed were fear, anger,
111 happiness, and neutrality. The pictures were immediately followed by a single or pair of dots (the
112 probe) which replaced the more positively valenced facial expression 87% of the time. The
113 participants were instructed to identify the number of dots as quickly and accurately as possible by
114 pressing one of two keys on the keyboard. The sham condition was identical except for a 50% chance
115 of the dot replacing either valence.

116 **Assessments and outcomes**

117 Hamilton Depression Rating Scale (HDRS; Hamilton, 1960) and Beck Depression Inventory-II (BDI-II;
118 Beck et al., 1988) were used as outcomes and these were measured at baseline, immediately after
119 the two-week intervention, and 1 month post-intervention. These showed good internal consistency
120 with Cronbach's Alpha at 0.771, 0.813 and 0.814 (HDRS) and 0.918, 0.927 and 0.931 (BDI-II)
121 respectively. Reviewers underwent training using case examples. Throughout the trial, bi-weekly
122 supervision meetings were held to maintain consistent rating standards. Any deviations were
123 resolved through consensus among the reviewers. However, we did not formally assess the ICC
124 between interviewers.

125 Baseline AB was measured in a paradigm equal to a single round of the sham condition but with a
126 new set of facial stimuli. Reaction times (RT) for responding to the probe by pressing one of two
127 designated keys on the keyboard were measured. The more negative expressions (e.g. neutral vs
128 positive) was defined as stimulus, thus defining valid trials as the ones where the dot-probe replaced
129 the more negative expression. In the invalid trials, the dot-probe replaced the least negative picture.
130 As there were no neutral-neutral trials, only the vigilance and avoidance scores were calculated. Each
131 individual reaction time of the valid scores was subtracted from the averaged score of the invalid
132 trials. Positive difference scores were averaged per participant and termed "vigilance" and negative
133 difference scores were averaged per participant and termed "avoidance". A vigilance-avoidance ratio
134 was also calculated. For comparison, traditional AB scores were also included where the mean RT of
135 the valid negative trials was subtracted from the mean RT of the invalid scores.

136 **Statistical analysis**

137 Statistical analyses were performed using R[31] in RStudio v2023.12.0[32]. There were missing data
138 sets on HDRS 1-month (n=30 (10%)) and BDI-II 1-month (n=28 (9%)). These were excluded from the 1
139 month analyses. Missing data points (n=13) were replaced with a series mean as they were missing

140 completely at random. Descriptives, including correlation analyses, were conducted for baseline
141 measurements. A regression-based moderator analysis was performed using the PROCESS macro
142 v4.3 [33] and assumptions were tested and met according to Hayes [34]. The predictor was set as
143 ABM, the moderator as baseline AB and outcome as BDI-II and HDRS at post-intervention or 1 month
144 post-intervention. The threshold for significance was set at 0.05. If significant, the interaction terms
145 were probed at the 16th, 50th and 84th percentiles and regions of significance were examined using
146 the Johnson-Neyman technique. Bootstrapping was performed to obtain robust confidence intervals
147 for the interaction term (n=5000). All regression analyses were controlled for the respective
148 depression score at baseline.

149 The attention bias data was reduced by first removing trials outside 200-2000ms. Next, answers with
150 the wrong location were removed. Missing data was imputed using series mean. The reduction left
151 96.23% of the trials. No data points were considered multivariate outliers according to the criteria of
152 being positive on 2 out of 3 on Mahalanobi's distance, Cook's distance and/or centered leverage, as
153 applied in [18]. After randomization, 37 individuals were found to fill the criteria for MDD (MDD+),
154 thus violating the inclusion criteria. Explorative analyses were run for the MDD+ group and selecting
155 for antidepressant status.

156 Reliability for the response-based score was measured using split-half analysis using even and odd
157 trial numbers to account for training effects [35]. All reliability correlation coefficients were
158 calculated using Spearman's rho and corrected with the Spearman-Brown prophecy formula. A
159 sensitivity power analysis was calculated using GPower [36].

160

161 **Results**

162 **Baseline characteristics**

163 Demographics are shown in Table 1. A correlation matrix between study variables is shown in Table
164 2. HDRS and BDI showed a significant correlation coefficient of 0.65, but response-based AB at

165 baseline showed a non-significant correlation of 0.05 with BDI-II and 0.02 with HDRS. Mean negative
 166 vigilance was 88.7ms (31.1ms), mean negative avoidance -131ms (57.9ms) and the vigilance-
 167 avoidance-ratio was 0.768 (0.418). Analyzing baseline AB by status of depression with independent
 168 two-sided t-test showed a significantly higher value for vigilance in the Major Depressive Disorder
 169 subgroup (MDD+) (MDD+: 100.0 ms vs MDD-: 87.1 ms, p=0.03) but non-significant differences in
 170 mean avoidance (MDD+ -138.0 ms (54.9ms) vs MDD- 130.0 ms (58.3ms), p=0.422). Eighty
 171 participants were using SSRIs or SNRIs (AD+), but there was no difference in mean vigilance (AD+:
 172 91.9ms(28.9ms) vs AD-:87.5(31.9ms), p=0.30) or in mean avoidance in these groups (AD+: -
 173 133ms(58.3ms) vs AD-:-130ms(57.4ms), p= 0.65). Traditional score AB at baseline across the sample
 174 was not significantly different from zero (mean -1.07ms, CI [-4.25 – 2.12], t(301)=-0.659, p=0.51).

175 **Table 1. Demographics (means (SD) or frequencies).**

	Placebo (n=148)	ABM (n=153)
Sex (females)	103	109
Age	41.5 (13.6)	40.2 (12.7)
Education level (ISCED) ^a	6.0 (1.2)	6.0 (1.1)
HDRS pre-intervention	8.3 (5.1)	9.3 (6,0)
HDRS post-intervention	8.7 (5.7)	8.4 (6,0)
HDRS post 1 month	8.1 (5.7)	8.6 (5.9)
BDI-II pre-intervention	13.5 (9.7)	15.1 (10.6)
BDI-II post-intervention	11.0 (9.7)	11.5 (10.5)
BDI-II post 1 month ^b	10.6 (9.5)	12.3 (10.1)
AB bl traditional ms	-1.2 (28.0)	-0.9 (28.0)
AB bl vigilance ms	87.0 (33.7)	90.1 (28.2)
AB bl avoidance ms	-130.0 (55.0)	-131.0 (60.3)
AB vigilance-avoidance ratio	0.7 (0.1)	0.7 (0.2)
Compliance ^c	80.0% (21.5)	83.4% (15.0)

Note. AB = Attentional Bias. ABM = Attention Bias Modification. BDI-II = Beck Depression Inventory II. HDRS =Hamilton Depression Rating Scale. bl = baseline.

^a Missing data for 6 in the placebo group, 8 in the ABM group

^b Missing data for 17 in the placebo group and 11 in the ABM group

^c percentage of max 2688 trials

176 **Table 2. Correlation matrix of psychometric scores.**

Variable	1	2	3	4	5	6	7	8	9
1 BDI-II baseline	--								
2 BDI-II post	.81**	--							
3 BDI-II 1 month	.73**	.78**	--						
4 HDRS baseline	.65**	.56**	.48**	--					
5 HDRS post	.60**	.69**	.58**	.64**	--				

6	HDRS 1 month	.46**	.48**	.69**	.47**	.59**	--		
7	AB baseline traditional	-.02	.02	.04	-.06	.01	.04	--	
8	AB baseline avoidance	.02	.06	.06	.07	.00	.05	.34**	--
9	AB baseline vigilance	.05	-.00	-.01	.02	-.01	-.01	-.28**	-.77**

Note. AB = Attention Bias. BDI-II = Beck Depression Inventory II. HDRS =Hamilton Depression Rating Scale. Pearson correlation is used for all measures.

** Correlation is significant at the 0.01 level (2-tailed).

177

178 The dot-probe reaction times showed high split-half reliability (valid: $r=0.96$, invalid: $r = 0.97$) and the
 179 correlation between mean average RT for valid and invalid trials were high ($r=0.96$). The split-half
 180 reliability for average vigilance was 0.86 and 0.54 for avoidance, respectively. Subanalyses for
 181 stimulus duration showed a reduction in reliability for both durations in vigilance (500ms: mean
 182 $r=0.70$, 1000ms: mean $r=0.74$) and increase at 1000ms in avoidance (500ms: mean $r: 0.48$, 1000ms:
 183 mean $r: 0.58$). Based on the reliability measurement, vigilance was used as measure of AB in the
 184 moderator analyses.

185

186 Moderation analysis

187 There was a statistically significant improvement in HDRS at post-intervention in the intervention
 188 group compared to the sham group ($F(1,309) = 6.78$, $\eta^2 = .02$, $p < .01$], see Jonassen et al 2019 for
 189 further details). Response-based baseline vigilance AB scores did not moderate the effect of ABM on
 190 change in any of the outcomes.

191 For HDRS at post-intervention: $F(4,295)=13.702$, $p<0.001$, $MSE=20.242$. R^2 -change: 0.001,
 192 $F(1,295)=0.303$, $p=0.582$, controlling for baseline HDRS. The slopes of the interaction effect are
 193 represented in Fig 1. The bootstrapping confidence interval for HDRS post-intervention was
 194 0.024 - 0.037, i.e., covering zero.

195 Baseline vigilance AB scores did not moderate the effect of ABM on reduction in BDI at post-
 196 intervention: $F(4,295)=0.949$, $p<0.0001$, $MSE:36.107$. R^2 -change: 0.004, $F(1,295)=1.1567$, $p=0.283$.
 197 Bootstrap CI: -0.014-0.0669. Excluding the (MDD+) did not affect the results.

198 Baseline vigilance AB scores did not moderate the effect of ABM on change in HDRS at 1 month
199 follow-up: $F(4, 265)=22.719$, $p<0.001$, MSE: 26.242. R^2 -change 0.000, $F(1,265)=0.000$, $p=0.247$.
200 Bootstrap CI: -0.070-0.016. Excluding the (MDD+) did not affect the results.

201 Baseline AB did not moderate the effect of ABM on change in BDI at 1 month follow-up:
202 $F(4,267)=13.361$, $p<0.001$, MSE:44.700. R^2 -change: 0.001, $F(1,267)=0.021$, $p=0.885$.
203 Bootstrap CI: -0.050-0.041. Excluding the (MDD+) did not affect the result. For full results, see
204 supplementary information.

205 **Fig 1. Moderator analysis of baseline AB on depression outcomes**

206
207 *Note. A.* Change in HDRS from baseline to post-intervention. *B.* Change in HDRS from baseline to 1
208 month. *C.* Change in BDI-II from baseline to post-intervention. *D.* Change in BDI-II from baseline to 1
209 month. Neither of the interaction effects were significant. ABM = Attention Bias Modification. BDI-II =
210 Beck Depression Inventory II. HDRS =Hamilton Depression Rating Scale. RRS-B Rumination Response
211 Scale – Brooding subscale

212

213 **Discussion**

214 The present study investigated response-based baseline AB as moderator for the effect of ABM on
215 depressive symptoms in a sample of participants with residual symptoms. No moderator effect was
216 found in either depression outcome at post-intervention or after 1 month.

217 Given the assertion that the central mechanism of ABM is correction of AB, the lack of a moderating
218 effect of baseline AB is surprising [37]. Still, this is in line with the only other moderator study on
219 baseline AB, where a negative AB at baseline did not moderate the change in depression in a non-
220 clinical population [21]. These results might represent a false negative as the analysis of moderation
221 probably was numerically underpowered (three arms, $n=77$) in addition to the use of the unreliable
222 traditional AB score. On the other hand, pre-selecting for a group with a moderate negative baseline
223 using a more reliable score, Hsu et al (2021) gave a significant effect of 0.72 points reduction per

224 week over four weeks on the HRSD. This could indicate an effect of pre-selecting on AB, but as no
225 control group was included, this remains uncertain.

226 Baseline AB as moderator for the effect of ABM has been more extensively studied in anxiety, though
227 results are mixed. Amir et al (2011) used a dot-probe task and found baseline AB towards threat to
228 moderate the response to the intervention in individuals with generalized social phobia. On the other
229 hand, in a study including children with social anxiety disorder, no moderating effect of baseline AB
230 was found on clinical outcome [38].

231 There are several explanations for the lack of moderation effect in our study. First, there was no
232 significant mean negative traditional AB at baseline. This is surprising, considering the results of a
233 meta-analysis where previously depressed individuals were found to have a negative traditional AB,
234 comparable to the AB found among currently depressed individuals [7]. Still, in never-depressed
235 people a neutral average AB is not the norm, but rather a positive bias [39]. As such, the level in our
236 sample represents a negative deviation from never-depressed.

237 Second, though the response-based AB calculation showed high reliability, it was not correlated with
238 any of the baseline depression scores, thus possibly being of questionable validity as a measurement
239 of depression. This corroborates previous findings on depression scores and AB measurement
240 [40,41]. The group differences in AB between depressed and non-depressed has been a consistent
241 finding and thus leaves the question of what the relationship between AB and depression represents.
242 The use of sum-scores as outcome may be conceal the effect as depression represents a highly
243 heterogenous diagnosis but no subscale to link depression to attention bias has been identified or
244 agreed [40,42].

245 Third, some choices in the baseline AB measurement paradigm may have affected the result. In
246 Kaiser et al (2018), the combination of emotionally congruent information in combination with self-
247 referential cues were the most potent at eliciting negative AB. The importance of relevance to the
248 participant was found for positive biases in Pool et al (2016). The dot-probe task may be less apt at

249 assessing AB due to the lack of self-referential material in our study. Stimulus lengths have also been
250 found to affect the AB detection. In our study, a stimulus length of 500 ms and 1000 ms was set at a
251 ratio of 1:1. Donaldson et al (2007) found a significant negative baseline AB in depressed individuals
252 when extending stimulus presentations to 1000 ms, which was not found at 500 ms. Further, eye-
253 tracking-studies have supported the notion of a bias in the latter stages of attention in depression
254 [5]. If AB is dynamic, rather than static, mean reaction times derived from longer stimulus durations
255 may provide a more reliable measurement, such as those found in eye-tracking studies (Skinner et
256 al., 2018).

257 Fourth, the low depression levels in the current sample may be of relevance to the null finding. With
258 a baseline BDI-II score of 14.3 in the sample, smaller improvements would be expected than in a
259 clinically depressed sample. Still, a baseline AB has been found in samples with lower baseline BDI
260 scores. In Arenliu et al (2023), the baseline score of BDI-II in a non-clinical population was 11.4, lower
261 than our baseline, and still a clear AB was found, though by using eye tracking instead of dot-probe.
262 In another sample, Joorman and Gotlib (2007) found a baseline AB in both depressed and formerly
263 depressed patients, the latter with a mean BDI of 5.21, using a dot-probe stimulation period of
264 1000ms. It is therefore unclear whether the low level of depression may have affected the result, but
265 limited opportunity for change in the outcome will anyhow limit the variance to explain.

266 Fifth, 27% (n=80) of the current sample used antidepressant medication, which could partly explain
267 the small negative traditional AB. SSRIs have been found to reduce attentional vigilance to threat in
268 healthy volunteers [46] but has to our knowledge not been studied in a clinically depressed
269 population Likewise, differences in AB using eye-tracking also revealed differences between
270 medicated and non-medicated individuals with MDD [47]. Still, considering the non-significant
271 difference in baseline response-based AB between antidepressant-users and non-users, the effect
272 does not seem to be the explain the lack of negative AB.

273 It is difficult to know if previous psychotherapy affected the baseline measurement here. The

274 research is scarce but a significant reduction after both CBT and positive psychology interventions in
275 AB using eye-tracking technology has been found [48]. Being a different detection method, it is not
276 possible to translate these findings to our study as the detection methods have been found to be
277 largely uncorrelated [25]. Furthermore, information of the types of pre-intervention psychotherapy
278 was not collected.

279 Sixth, the lack of moderation effect may be attributed to the limited effect of the intervention and
280 the similarity of the sham comparator. The total change in HDRS for the intervention group was small
281 (-0.9 points vs +0.5 for the sham condition) and not significant for BDI-II, possibly due to the low
282 baseline depression levels. The use of a sham condition as control to address the clinical utility of
283 ABM has been questioned because it is not a clinically relevant alternative [49] and also due to the
284 effect on attentional processes by both conditions [22,50]. It may also alter moderating factors of AB
285 such as attentional control (Basanovic and MacLeod, 2017) and improvement in attentional control,
286 following ABM, has been found to correlate with clinical improvement [22,50]. It may therefore mask
287 the effect by itself affecting AB, reducing the chance of finding a statistically significant result. Still,
288 Hsu et al (2021), pre-selecting for moderate AB, found a significant difference in depression scores
289 between sham and active ABM, but no difference between sham and assessment-only.

290 Seventh, in this study there was a significantly larger change in HDRS in the ABM group than the
291 control group, but the change in the traditional AB was small and not significantly, as previously
292 reported [10]. Macleod and Grafton (2016) showed how a lack of significant change in AB often
293 resulted in lack of change in depression outcomes. The eliciting of a significant change in AB is
294 necessary to determine if the procedure was effective, rather than making claims about the effect of
295 the process [52]. This may have affected the size of the reduction and may be a consequence of the
296 mentioned similarity in conditions.

297

298 **Strengths and limitations**

299 This RCT represents the largest RCT in individuals with residual depression, using a well-known
300 procedure with stringent conditions. In addressing the residual nature of depression, it answers an
301 important question of whether using baseline AB moderates the effect of ABM. By applying the
302 response-based AB measure, a high reliability secures the frequently overlooked problem of poor
303 reliability on power calculations [26], and the consequent underestimation of the number of
304 participants needed. As this is secondary analysis no a priori power calculation was performed, but a
305 sensitivity power analysis [53] using GPower 3.1.9.7 fixing $\alpha = 0.05$ and power at 0.90 with $n=301$
306 returns a possible detection of effect sizes of $f^2 = 0.04$ indicating an unlikely false negative result [36].
307 Generalization to other populations is limited due to lack of generalizability due to low baseline
308 depression scores. Another issue lies in the lack of sad facial expressions in the stimuli as this has
309 shown to be the most potent stimuli in eliciting AB in depression. Furthermore, the analysis of single
310 moderators is possibly not sufficient to define the treatment of MDD [54] and multivariate
311 approaches may be more clinically useful, such as the Personalized Advantage Index that has shown
312 promising results in psychotherapy research [55].

313 **Future directions**

314 As previously suggested, the validity of the response-based index should be studied and outcome
315 measures evaluated further in clinically depressed populations [40]. Further, we support the notion
316 that both cleaning of data and reliability measure should be registered before inclusion as suggested
317 by Molloy & Anderson (2020). Furthermore, the use of a sham condition as control group in clinical
318 trials should be carefully considered due to its similarity to the active intervention.

319 **Conclusion**

320 A response-based baseline measure of attention bias did not moderate the effect of ABM despite a
321 reliable AB measure, thus rendering it unsuited to define individuals with increased effect of ABM.

322 Furthermore, it was not correlated with levels of depression and further research to clarify this
323 relationship and the psychometric validity is needed.

324

325 **Acknowledgements**

326 **Acknowledgements:** We want to thank Luigi Maglanoc, Eva Hilland, Inger Marie Andreassen, Adrian
327 Dahl Askelund, Dani Beck, Sandra Aakjær Bruun, Jenny Tveit Kojan, Nils Eivind Holth Landrø, Elise
328 Solbu Kleven and Julie Wasmuth for their contribution to the data collection. Further, we thank Kari
329 Agnes Myhre, Erlend Bøen, MD, PhD and Torkil Berge at Diakonhjemmet Hospital, Division of
330 Psychiatry, for help and support during the recruiting period. We also thank our external recruitment
331 sites, Unicare, Tore C. Stiles at Coperiosenteret AS, Torgny Syrstad, MD, Synergi Helse AS and
332 Lovisenberg Hospital.

333

334

335

336 **References**

- 337 1. Global, regional, and national burden of 12 mental disorders in 204 countries and territories,
338 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. *The Lancet*
339 *Psychiatry*. 2022 Feb 1;9(2):137–50. doi:10.1016/S2215-0366(21)00395-3.
- 340 2. Cuijpers P, Quero S, Dowrick C, Arroll B. Psychological Treatment of Depression in Primary Care:
341 Recent Developments. *Curr Psychiatry Rep*. 2019 Nov 23;21(12):129. doi:10.1007/s11920-019-
342 1117-x.
- 343 3. Beck AT. The Evolution of the Cognitive Model of Depression and Its Neurobiological Correlates.
344 *AJP*. 2008 Aug;165(8):969–77. doi:10.1176/appi.ajp.2008.08050721.
- 345 4. Peckham AD, McHugh RK, Otto MW. A meta-analysis of the magnitude of biased attention in
346 depression. *Depression and Anxiety*. 2010;27(12):1135–42. doi:10.1002/da.20755.

- 347 5. Suslow T, Hußlack A, Kersting A, Bodenschatz CM. Attentional biases to emotional information in
348 clinical depression: A systematic and meta-analytic review of eye tracking findings. *J Affect*
349 *Disord.* 2020 Sep 1;274:632–42. doi:10.1016/j.jad.2020.05.140.
- 350 6. Joormann J, Gotlib IH. Selective attention to emotional faces following recovery from depression.
351 *Journal of Abnormal Psychology.* 2007 Feb;116(1):80–5. doi:10.1037/0021-843X.116.1.80.
- 352 7. Shamai-Leshem D, Linetzky M, Bar-Haim Y. Attention Biases in Previously Depressed Individuals:
353 A Meta-Analysis and Implications for Depression Recurrence. *Cogn Ther Res.* 2022 Dec
354 1;46(6):1033–48. doi:10.1007/s10608-022-10331-y.
- 355 8. MacLeod C, Rutherford E, Campbell L, Ebsworthy G, Holker L. Selective attention and emotional
356 vulnerability: Assessing the causal basis of their association through the experimental
357 manipulation of attentional bias. *Journal of Abnormal Psychology.* 2002 Feb;111(1):107–23.
358 doi:10.1037/0021-843X.111.1.107.
- 359 9. Hsu KJ, Shumake J, Caffey K, Risom S, Labrada J, Smits JAJ, et al. Efficacy of attention bias
360 modification training for depressed adults: a randomized clinical trial. *Psychological Medicine.*
361 2021 Mar 26;1–9. doi:10.1017/S0033291721000702.
- 362 10. Jonassen R, Harmer CJ, Hilland E, Maglanoc LA, Kraft B, Browning M, et al. Effects of Attentional
363 Bias Modification on residual symptoms in depression: a randomized controlled trial. *BMC*
364 *Psychiatry.* 2019 May 8;19(1):141. doi:10.1186/s12888-019-2105-8.
- 365 11. Cristea IA, Kok RN, Cuijpers P. Efficacy of cognitive bias modification interventions in anxiety and
366 depression: meta-analysis. *Br J Psychiatry.* 2015 Jan;206(1):7–16.
367 doi:10.1192/bjp.bp.114.146761.
- 368 12. Fodor LA, Georgescu R, Cuijpers P, Szamoskozi Ş, David D, Furukawa TA, et al. Efficacy of
369 cognitive bias modification interventions in anxiety and depressive disorders: a systematic
370 review and network meta-analysis. *The Lancet Psychiatry.* 2020 Jun 1;7(6):506–14.
371 doi:10.1016/S2215-0366(20)30130-9.
- 372 13. Hallion LS, Ruscio AM. A meta-analysis of the effect of cognitive bias modification on anxiety and
373 depression. *Psychological Bulletin.* 2011 Nov;137(6):940–58. doi:10.1037/a0024355.
- 374 14. Li J, Ma H, Yang H, Yu H, Zhang N. Cognitive bias modification for adult’s depression: A systematic
375 review and meta-analysis. *Front Psychol.* 2023 Jan 19;13:968638.
376 doi:10.3389/fpsyg.2022.968638.
- 377 15. Xia H sha, Li Y xi, Zhang Q yun, Zhong D ling, Liu X bo, Gou X yun, et al. Attention bias
378 modification for depression: A systematic review and meta-analysis. *Front Psychiatry.* 2023 Mar
379 10;14:1098610. doi:10.3389/fpsyt.2023.1098610.
- 380 16. Herrman H, Patel V, Kieling C, Berk M, Buchweitz C, Cuijpers P, et al. Time for united action on
381 depression: a Lancet–World Psychiatric Association Commission. *The Lancet.* 2022 Mar
382 5;399(10328):957–1022. doi:10.1016/S0140-6736(21)02141-3.
- 383 17. MacLeod C, Grafton B, Notebaert L. Anxiety-Linked Attentional Bias: Is It Reliable? *Annu Rev Clin*
384 *Psychol.* 2019 May 7;15(1):529–54. doi:10.1146/annurev-clinpsy-050718-095505.

- 385 18. Bø R, Kraft B, Jonassen R, Harmer CJ, Hilland E, Stiles TC, et al. Symptom severity moderates the
386 outcome of attention bias modification for depression: An exploratory study. *Journal of*
387 *Psychiatric Research*. 2021 Jun;138:528–34. doi:10.1016/j.jpsychires.2021.04.027.
- 388 19. Arditte KA, Joormann J. Rumination Moderates the Effects of Cognitive Bias Modification of
389 Attention. *Cogn Ther Res*. 2014 Apr;38(2):189–99. doi:10.1007/s10608-013-9581-9.
- 390 20. Amir N, Taylor CT, Donohue MC. Predictors of Response to an Attention Modification Program in
391 Generalized Social Phobia. *J Consult Clin Psychol*. 2011 Aug;79(4):533–41.
392 doi:10.1037/a0023808.
- 393 21. Yang W, Ding Z, Dai T, Peng F, Zhang JX. Attention Bias Modification training in individuals with
394 depressive symptoms: A randomized controlled trial. *Journal of Behavior Therapy and*
395 *Experimental Psychiatry*. 2015 Dec 1;49:101–11. doi:10.1016/j.jbtep.2014.08.005.
- 396 22. McNally RJ, Enock PM, Tsai C, Tousian M. Attention bias modification for reducing speech
397 anxiety. *Behav Res Ther*. 2013 Dec;51(12):882–8. doi:10.1016/j.brat.2013.10.001.
- 398 23. Meissel EEE, Liu H, Stevens ES, Evans TC, Britton JC, Letkiewicz AM, et al. The Reliability and
399 Validity of Response-Based Measures of Attention Bias. *Cogn Ther Res*. 2022 Feb 1;46(1):146–60.
400 doi:10.1007/s10608-021-10212-w.
- 401 24. Rodebaugh TL, Scullin RB, Langer JK, Dixon DJ, Huppert JD, Bernstein A, et al. Unreliability as a
402 Threat to Understanding Psychopathology: The Cautionary Tale of Attentional Bias. *J Abnorm*
403 *Psychol*. 2016 Aug;125(6):840–51. doi:10.1037/abn0000184.
- 404 25. Waechter S, Nelson AL, Wright C, Hyatt A, Oakman J. Measuring Attentional Bias to Threat:
405 Reliability of Dot Probe and Eye Movement Indices. *Cogn Ther Res*. 2014 Jun 1;38(3):313–33.
406 doi:10.1007/s10608-013-9588-2.
- 407 26. Parsons S, Kruijt AW, Fox E. Psychological Science Needs a Standard Practice of Reporting the
408 Reliability of Cognitive-Behavioral Measurements. *Advances in Methods and Practices in*
409 *Psychological Science*. 2019 Dec 1;2(4):378–95. doi:10.1177/2515245919879695.
- 410 27. Evans TC, Britton JC. Improving the psychometric properties of dot-probe attention measures
411 using response-based computation. *Journal of Behavior Therapy and Experimental Psychiatry*.
412 2018 Sep 1;60:95–103. doi:10.1016/j.jbtep.2018.01.009.
- 413 28. Browning M, Holmes EA, Charles M, Cowen PJ, Harmer CJ. Using Attentional Bias Modification as
414 a Cognitive Vaccine Against Depression. *Biological Psychiatry*. 2012 Oct 1;72(7):572–9.
415 doi:10.1016/j.biopsych.2012.04.014.
- 416 29. Hamilton M. A RATING SCALE FOR DEPRESSION. *Journal of Neurology, Neurosurgery &*
417 *Psychiatry*. 1960 Feb 1;23(1):56–62. doi:10.1136/jnnp.23.1.56.
- 418 30. Beck AT, Steer RA, Carbin MG. Psychometric properties of the Beck Depression Inventory:
419 Twenty-five years of evaluation. *Clinical Psychology Review*. 1988 Jan 1;8(1):77–100.
420 doi:10.1016/0272-7358(88)90050-5.
- 421 31. R Core Team. R: A language and environment for statistical computing. Vienna, Austria: R
422 Foundation for Statistical Computing; 2024.
- 423 32. RStudio Team. Rstudio [Internet]. RStudio, PBC; 2024. Available from: <https://www.rstudio.com/>

- 424 33. Hayes A. PROCESS [Internet]. 2022. Available from: www.processmacro.org
- 425 34. Hayes AF. Introduction to mediation, moderation, and conditional process analysis: a regression-
426 based approach. Second edition. New York, London: The Guilford Press; 2018. (Methodology in
427 the social sciences).
- 428 35. Pronk T, Molenaar D, Wiers RW, Murre J. Methods to split cognitive task data for estimating
429 split-half reliability: A comprehensive review and systematic assessment. *Psychon Bull Rev*. 2022
430 Feb 1;29(1):44–54. doi:10.3758/s13423-021-01948-3.
- 431 36. Faul F, Erdfelder E, Buchner A, Lang AG. Statistical power analyses using G*Power 3.1: Tests for
432 correlation and regression analyses. *Behavior Research Methods*. 2009 Nov;41(4):1149–60.
433 doi:10.3758/BRM.41.4.1149.
- 434 37. Grafton B, MacLeod C, Rudaizky D, Holmes EA, Salemink E, Fox E, et al. Confusing procedures
435 with process when appraising the impact of cognitive bias modification on emotional
436 vulnerability. *The British Journal of Psychiatry*. 2017 Nov;211(5):266–71.
437 doi:10.1192/bjp.bp.115.176123.
- 438 38. Pergamin-Hight L, Pine DS, Fox NA, Bar-Haim Y. Attention bias modification for youth with social
439 anxiety disorder. *Journal of Child Psychology and Psychiatry*. 2016;57(11):1317–25.
440 doi:10.1111/jcpp.12599.
- 441 39. Pool E, Brosch T, Delplanque S, Sander D. Attentional bias for positive emotional stimuli: A meta-
442 analytic investigation. *Psychological Bulletin*. 2016;142(1):79–106. doi:10.1037/bul0000026.
- 443 40. Beevers CG, Mullarkey MC, Dainer-Best J, Stewart RA, Labrada J, Allen JJB, et al. Association
444 Between Negative Cognitive Bias and Depression: A Symptom-Level Approach. 2019;
- 445 41. Marchetti I, Everaert J, Dainer-Best J, Loeys T, Beevers CG, Koster EHW. Specificity and overlap of
446 attention and memory biases in depression. *Journal of Affective Disorders*. 2018 Jan 1;225:404–
447 12. doi:10.1016/j.jad.2017.08.037.
- 448 42. Fried E. Moving forward: how depression heterogeneity hinders progress in treatment and
449 research. *Expert Review of Neurotherapeutics*. 2017 May 4;17(5):423–5.
450 doi:10.1080/14737175.2017.1307737.
- 451 43. Kaiser RH, Snyder HR, Goer F, Clegg R, Ironside M, Pizzagalli DA. Attention Bias in Rumination and
452 Depression: Cognitive Mechanisms and Brain Networks. *Clin Psychol Sci*. 2018 Nov;6(6):765–82.
453 doi:10.1177/2167702618797935.
- 454 44. Skinner IW, Hübscher M, Moseley GL, Lee H, Wand BM, Traeger AC, et al. The reliability of
455 eyetracking to assess attentional bias to threatening words in healthy individuals. *Behav Res*.
456 2018 Oct 1;50(5):1778–92. doi:10.3758/s13428-017-0946-y.
- 457 45. Arenliu A, Konjufca J, Meiran N, Weine S, Langenecker SA. Attentional Bias Among High and Low
458 Ruminators: Eye Tracking Study in a Non-Clinical Population. *SAGE Open*. 2023 Apr
459 1;13(2):21582440231170804. doi:10.1177/21582440231170804.
- 460 46. Murphy SE, Yiend J, Lester KJ, Cowen PJ, Harmer CJ. Short-term serotonergic but not
461 noradrenergic antidepressant administration reduces attentional vigilance to threat in healthy
462 volunteers. *International Journal of Neuropsychopharmacology*. 2009 Mar 1;12(2):169–79.
463 doi:10.1017/S1461145708009164.

- 464 47. Wells TT, Clerkin EM, Ellis AJ, Beevers CG. Effect of Antidepressant Medication Use on Emotional
465 Information Processing in Major Depression. *Am J Psychiatry*. 2014 Feb 1;171(2):195–200.
466 doi:10.1176/appi.ajp.2013.12091243.
- 467 48. Vazquez C, Duque A, Blanco I, Pascual T, Poyato N, Lopez-Gomez I, et al. CBT and positive
468 psychology interventions for clinical depression promote healthy attentional biases: An eye-
469 tracking study. *Depression and Anxiety*. 2018;35(10):966–73. doi:10.1002/da.22786.
- 470 49. Blackwell SE, Woud ML, MacLeod C. A Question of Control? Examining the Role of Control
471 Conditions in Experimental Psychopathology using the Example of Cognitive Bias Modification
472 Research. *The Spanish Journal of Psychology*. 2017 Jan;20(e54):1–13. doi:10.1017/sjp.2017.41.
- 473 50. Heeren A, Mogoşe C, McNally RJ, Schmitz A, Philippot P. Does attention bias modification
474 improve attentional control? A double-blind randomized experiment with individuals with social
475 anxiety disorder. *Journal of Anxiety Disorders*. 2015 Jan 1;29:35–42.
476 doi:10.1016/j.janxdis.2014.10.007.
- 477 51. Basanovic J, MacLeod C. Does anxiety-linked attentional bias to threatening information reflect
478 bias in the setting of attentional goals, or bias in the execution of attentional goals? *Cognition*
479 and Emotion. 2017 Apr 3;31(3):538–51. doi:10.1080/02699931.2016.1138931.
- 480 52. MacLeod C, Grafton B. Anxiety-linked attentional bias and its modification: Illustrating the
481 importance of distinguishing processes and procedures in experimental psychopathology
482 research. *Behaviour Research and Therapy*. 2016 Nov 1;86:68–86.
483 doi:10.1016/j.brat.2016.07.005.
- 484 53. Lakens D. Sample Size Justification. *Collabra: Psychology*. 2022 Mar 22;8(1):33267.
485 doi:10.1525/collabra.33267.
- 486 54. Cohen ZD, DeRubeis RJ. Treatment Selection in Depression. *Annu Rev Clin Psychol*. 2018 May
487 7;14(1):209–36. doi:10.1146/annurev-clinpsy-050817-084746.
- 488 55. van Bronswijk SC, DeRubeis RJ, Lemmens LHJM, Peeters FPML, Keefe JR, Cohen ZD, et al.
489 Precision medicine for long-term depression outcomes using the Personalized Advantage Index
490 approach: cognitive therapy or interpersonal psychotherapy? *Psychol Med*. 2021;51(2):279–89.
491 doi:10.1017/S0033291719003192.
- 492 56. Molloy A, Anderson PL. Evaluating the reliability of attention bias and attention bias variability
493 measures in the dot-probe task among people with social anxiety disorder. *Psychological*
494 *Assessment*. 2020;32(9):883–8. doi:10.1037/pas0000912.
- 495







Fig1.tif